| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5692570 | European Urology | 2016 | 8 Pages |
Abstract
Prostate-specific antigen (PSA) is commonly used to evaluate response to treatment in metastatic castration-resistant prostate cancer. Expert recommendations discourage reliance on PSA changes earlier than 12 wk after treatment initiation. Our data suggest that early PSA changes are associated with survival in patients receiving abiraterone acetate.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Pasquale Rescigno, David Lorente, Diletta Bianchini, Roberta Ferraldeschi, Michael P. Kolinsky, Spyridon Sideris, Zafeiris Zafeiriou, Semini Sumanasuriya, Alan D. Smith, Niven Mehra, Anuradha Jayaram, Raquel Perez-Lopez, Joaquin Mateo, Chris Parker,